Business
Personalis, Inc. Announces New Data to be Presented at ASCO Virtual Scientific Meeting
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will
About this update from Personalis, Inc.
[{"type":"text","content":" MENLO PARK, Calif.--(BUSINESS WIRE)--\nPersonalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in abstracts to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, which will be held May 29-31, 2020.\n\n\nOne abstract showcases data from the ImmunoID NeXT Platform™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.\n\n\nAnother abstract highlights data from the Personalis NeXT Dx™ Test, one of the first cancer diagnostic platforms to profile approximately 20,000 genes in both the tumor exome and transcriptome, providing a comprehensive genomic testing solution that goes beyond many existing cancer diagnostic panels that focus on a few hundred genes. The Personalis NeXT Dx Test includes advanced analytics to provide a diagnostic report on genetic alterations in clinically-important cancer genes, as well as emerging immunotherapy composite biomarkers of medical importance.\n\n\nFollowing are details and links to the abstracts that will be presented at the online meeting.\n\n\n\n\nAbstract Number &\nSession Title\n\n\n\n\nTitle & Presenter\n\n\n\n\nDate\n\n\n\n\nLocation\n\n\n\n\n\n6557\nHead and Neck Cancers\n\n\n\n\nExome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck.\nPresenter: Charles Abbott\n\n\n\n\nMay 29, 2020\n\n\n\n\nOnline\n\n\n\n\n\ne15583\nDevelopmental Therapeutics—Molecularly Targeted Agents and Tumor Biology\n\n\n\n\nValidation of an exome and transcriptome based diagnostic platform enabling clinical cancer therapy selection and emerging composite biomarkers for immunotherapy.\nPresenter: Sebastian Saldivar\n\n\n\n\nMay 29, 2020\n\n\n\n\nOnline\n\n\n\n\n\nAbout Personalis, Inc.\n\n\nPersonalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s can...